Climacteric Symptoms Clinical Trial
Official title:
A 24-week, Single-center, Open-label Study to Evaluate Gut Microbiota, Immunity, Oxidative Stress and Autonomic Nerve System of Red Ginseng Extract in Subjects With Climacteric Symptoms.
Verified date | March 2019 |
Source | MedicalExcellence |
Contact | Youn Ju Lee |
Phone | 82-2-3482-7834 |
yj.lee[@]mediex.co.kr | |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to investigate the positive effects of red ginseng extract on intestinal bacterial changes and immunity, free radicals, antioxidant capacity, and autonomic nervous system changes in age of 40~75 men and women with climacteric symptoms for 24 weeks.
Status | Not yet recruiting |
Enrollment | 53 |
Est. completion date | February 2020 |
Est. primary completion date | February 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years to 75 Years |
Eligibility |
Inclusion Criteria: 1. Age of 40~75 men and women 2. Those who visited the menopausal clinic with complaints of climacteric symptoms due to functional deterioration of various organs such as fatigue, helplessness 3. Those who have agreed to voluntarily decide to participate and observe the instructions after hearing the detailed explanation of this human body application test Exclusion Criteria: 1. Those who have suspected symptoms of acute disease (severe infectious disease, severe trauma, severe diarrhea, vomiting, etc.) 2. Patients with a history of antibiotic treatment for more than 1 month within the last 6 months 3. Those who have gastrointestinal diseases (inflammatory growth disease, active peptic ulcer, etc.) or gastrointestinal surgery (except for simple appendectomy or hernia surgery) 4. Those taking health functional foods, lactic acid bacteria, and red ginseng extracts for the past year 5. Those who are currently participating in other clinical studies or human trials, or participating in clinical trials or human application tests within the past month |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
MedicalExcellence |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes in gut microbiota at 24 weeks vs baseline | 24 weeks | ||
Secondary | Changes in Total Oxidant Status(TOS in µmol/L) at 24 weeks vs baseline | 24 weeks | ||
Secondary | Changes in Total Antioxidant Status(TAS in mmol/L) at 24 weeks vs baseline | 24 weeks | ||
Secondary | Changes in Natural Killer(NK) cell activity at 24 weeks vs baseline | 24 weeks | ||
Secondary | Changes in Heart rate variability at 24 weeks vs baseline | 24 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00408863 -
Livial Intervention Following Breast Cancer; Efficacy, Recurrence and Tolerability Endpoints (LIBERATE)(COMPLETED)(P05885)
|
Phase 3 | |
Completed |
NCT02672189 -
Internet-based Cognitive Behavioral Therapy for Breast Cancer Patients With Climacteric Symptoms
|
Phase 3 | |
Recruiting |
NCT00622986 -
China Cimicifuga Trial of Climacteric Complaint Control
|
Phase 4 | |
Completed |
NCT00275964 -
Development of Active Safety Surveillance System for Traditional Chinese Medicine
|
Phase 4 |